Moderna Inc (MRNA): Next-Year EPS Estimate 44.93%
As of 2026-07-17, Moderna Inc (MRNA) has a next-year EPS growth estimate of 44.93%. Featured in 4 EPS revision reports, most recently on 2026-07-07.
On 2026-07-13, analyst consensus for MRNA's next-year EPS growth shifted from 43.60% to 44.93% — a positive change of 1.33 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at -19.44%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 44.93%
- EPS growth this year
- -19.44%
- EPS next quarter (est)
- -$2.04
- Last price
- $61.82
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 44.93% | -19.44% | -$2.04 | $61.82 |
| 2026-07-16 | 44.93% | -19.44% | -$2.04 | $63.15 |
| 2026-07-15 | 44.93% | -19.44% | -$2.04 | $68.28 |
| 2026-07-14 | 44.93% | -19.44% | -$2.04 | $67.44 |
| 2026-07-13 | 44.93% | -19.44% | -$2.04 | $67.01 |
| 2026-07-12 | 43.60% | -16.13% | -$2.03 | $68.27 |
| 2026-07-09 | 43.60% | -16.13% | -$2.03 | $76.56 |
| 2026-07-08 | 43.60% | -16.13% | -$2.03 | $73.80 |
| 2026-07-07 | 44.83% | -18.65% | -$2.03 | $79.77 |
| 2026-07-06 | 45.31% | -18.25% | -$2.06 | $81.80 |
| 2026-07-05 | 45.35% | -18.19% | -$2.06 | $79.76 |
| 2026-07-02 | 45.35% | -18.19% | -$2.06 | $79.76 |
| 2026-07-01 | 45.35% | -18.18% | -$2.06 | $72.50 |
| 2026-06-30 | 45.35% | -18.18% | -$2.06 | $70.03 |
| 2026-06-29 | 45.35% | -18.19% | -$2.06 | $69.70 |
| 2026-06-28 | 45.35% | -18.19% | -$2.06 | $67.27 |
| 2026-06-25 | 45.10% | -18.38% | -$2.06 | $59.75 |
| 2026-06-24 | 45.10% | -18.38% | -$2.06 | $60.42 |
| 2026-06-23 | 45.10% | -18.38% | -$2.06 | $61.00 |
| 2026-06-22 | 45.10% | -18.38% | -$2.06 | $59.35 |
| 2026-06-21 | 45.07% | -18.38% | -$2.06 | $63.96 |
| 2026-06-18 | 45.07% | -18.38% | -$2.06 | $63.96 |
| 2026-06-17 | 45.07% | -18.38% | -$2.06 | $61.80 |
| 2026-06-16 | 45.07% | -18.38% | -$2.06 | $55.40 |
| 2026-06-15 | 45.07% | -18.38% | -$2.06 | $52.13 |
| 2026-06-14 | 45.07% | -18.38% | -$2.06 | $49.91 |
| 2026-06-11 | 45.07% | -18.38% | -$2.06 | $49.64 |
| 2026-06-10 | 45.07% | -18.38% | -$2.06 | $45.99 |
| 2026-06-09 | 45.07% | -18.38% | -$2.06 | $47.73 |
| 2026-06-08 | 45.07% | -18.38% | -$2.06 | $47.60 |
Reports Featuring MRNA
- 2026-07-07
WBX +40.8% Leads EPS Revision Winners; NMAX Surges on 217.8pp EPS Upgrade
- 2026-07-06
Stock Surge Alert: WBX +47%, IOT +29%, MRNA +22% on EPS Revisions
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
Recent News
- S&P 500 ends lower; chips tumble and Moderna ralliesReuters Videos
- Stocks Struggle After OpenAI IPO Blow: Stock Market TodayKiplinger
- Trending: Netflix stock bounces back, Moderna surges postinvestor day, ON Semi plummetsYahoo Finance Video
- Healthcare stocks have become a haven for investors ditching techMarketWatch
- Moderna Shares Up on New Research Efforts for Autoimmune DisorderThe Wall Street Journal
- Why Moderna Stock Is Soaring and Leading the S&P 500 TodayBarrons.com
- From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola OutbreakNewsfile
- Moderna Stock's 6-Day Rally Ends in a Dive. Why It's One of the S&P 500's Biggest Losers Today.Barrons.com
- Modernas mRNA flu vaccine passes FDA AdCom, review underwayPharmaceutical Technology
- MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu VaccineStocktwits
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Moderna Inc's next-year EPS growth estimate?▾
As of 2026-07-17, Moderna Inc (MRNA) has a next-year EPS growth estimate of 44.93%, based on analyst consensus.
When was the latest EPS estimate revision for MRNA?▾
The most recent revision occurred on 2026-07-13, when analysts adjusted the next-year EPS growth estimate from 43.60% to 44.93%.
What sector and industry does Moderna Inc belong to?▾
Moderna Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MRNA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moderna Inc (MRNA) appears here because it was detected by our daily top-EPS-revision-performer screen.